From the University Departments of Clinical Medicine and Psychiatry,
The General Infirmary, Leeds The dangers of corticosteroid therapy in patients with rheumatoid arthritis make valuable any regime which would enable the effective dosage to be reduced. Some clinical reports have suggested that the introduction of a monoamine oxidase inhibitor to a scheme of corticosteroid dosage might result in a "steroid sparing" effect and thus improve the apparent therapeutic ratio of the steroid (Scherbel, 1957 (Scherbel, , 1958 Banghart, 1958) . Several uncontrolled studies have been reported. Gillhespy (1961) used nialamide in patients with moderately severe rheumatoid arthritis who had been under continuous treatment with steroids, and this enabled a subsequent reduction in dosage to be made in 83 per cent. without clinical deterioration. Other authors (Pratesi and Muzzolini, 1959; Cecchi and Ferraris, 1959; Sales-Sales, 1961; Krammer, 1961; Moretti and Staeffen, 1961) similarly claimed that arthritis was ameliorated with the aid of nialamide. All these workers believed that their results were related to a pharmacological effect either on the biochemistry of rheumatoid arthritis or on the metabolism of steroids.
However, it is known that nialamide has an antidepressive action (Scherbel and Harrison, 1959) and it is possible that an apparent "steroid sparing" effect might be due to the production of mood elevation and increased pain tolerance rather than to an interaction with steroids. A double-blind controlled trial has therefore been performed in patients with rheumatoid arthritis receiving corticosteroids to answer the questions:
(1) Does nialamide have a "steroid sparing" effect? (2) If so, is this a real effect on articular status or is it associated with the antidepressive action of the drug?
Material and Methods Thirty consecutive patients with definite rheumatoid arthritis by the diagnostic criteria of the American Rheumatism Association (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959) were admitted to the trial from those attending the outpatient clinic. They were selected on the basis of being able and willing to participate in the study, having been on a constant dose of corticosteroid equivalent to 7-5 mg. or more of prednisolone daily for a preceding period of at least 6 months, not having received gold or antimalarial drug therapy in that period, and having no history of jaundice.
Arthritic and psychiatric assessments were made immediately before the start of the trial and at periods of 4 and 8 weeks during the trial. At each assessment the following parameters were measured: patient's assessment of fitness in percentage; functional status in five grades, varying from normal (1) to complete crippling (5); the mean strength of two grips of each hand; the number of joints showing two of the signs, tenderness, swelling, and limitation of movement; haemoglobin level; erythrocyte sedimentation rate; serum glutamic NIALAMIDE AS A "STEROID-SPARING" AGENT oxaloacetic transaminase (s.g.o.t.), and serum glutamic pyruvic transaminase (s.g.p.t.).
Psychiatric assessment was undertaken by one of us (E.A.M.W.) in interviews with the patient and where possible with relatives. Particular attention was paid to the presence or absence of depression and to its severity. In view of the known ability of steroids to produce affective disturbance (Bleuler, 1954) , any relationship between the onset and duration of depressive symptoms and the administration of steroids was noted. In interviews at Week 4 and Week 8, further assessments were undertaken, and the improvement or deterioration in the affective state was recorded in three grades from slight (I) to marked (3).
The patients were treated over two consecutive 4-week periods. The design of the trial is illustrated in the During the first period they received the dose of corticosteroid on which they had been maintained for the previous 6 
Composition of Groups
The characteristics of the two groups of patients are shown in Table 1 .
There was no significant difference in any aspect, although the mean duration of arthritis in the group treated with the active drug was less than in those treated with the placebo. Mean grip strength was greater in patients receiving the placebo than in those receiving active drug, and the mean erythrocyte sedimentation rate was higher in the former, but these differences were not significant. The majority of patients had been receiving prednisolone; three were taking triamcinolone, and one methyl prednisolone.
Results
Table IL (overleaf) shows changes in the parameters assessed between Weeks 0 and 4 and Weeks 0 and 8.
Functional Status
Most patients retained their original status over the whole period. Two on placebo and three on nialamide showed deterioration by the end of the trial (Table II) 
Relationship between Psychiatric and Arthritic Assessment
The correlations between changes in the psychiatric assessment and arthritic status are shown in Table III (opposite). There was no correlation with the number of affected joints, haemoglobin, or erythrocyte sedimentation rate. A striking correlation at the P = 0 01 level existed between psychiatric change and change in the patients' estimation of fitness in both those receiving placebo and those receiving nialamide in the first 4 weeks. A similar trend was shown over the whole period, which was significant at the P = 0 05 level in the placebo group, but did not reach significance in the nialamide group. A significant correlation of strength of grip with psychiatric change was present in the first 4 weeks in those receiving nialamide.
Complications Complications (including those necessitating withdrawal from the trial) are shown in Table IV . Of the nine patients experiencing untoward effects during the administration of nialamide, three complained of nausea, but this was also present in two patients receiving placebo. Postural dizziness and insomnia were side-effects found only in patients receiving nialamide. Other symptoms in patients receiving placebo were headache for the first few days in one, a feeling of drowsiness in the first few days in a second, and pain in the limbs, faintness, and nightmares in a third. (15-3 units) at the beginning and end of the trial, but again these differences were not significant.
Discussion
Any method permitting reduction of steroid dosage in patients with rheumatoid arthritis without increased activity is worthy of investigation. It is important, therefore, to examine the claim that nialamide acts in such a manner. Gillhespy (1961) has postulated that monoamine oxidase inhibitors may compensate for biochemical disturbances recorded in rheumatoid arthritis (Michotte, 1958; Schmid, Scheiffarth, and Zicha, 1959) or may delay hepatic inactivation of cortisone and related compounds. However, it is well known that nialamide may produce elevation of mood (Scherbel and Harrison, 1959) , and it may be that the apparent "steroid sparing" effect of nialamide is due to this indirect action which enables patients to tolerate the pain of the arthritis better and thus allow a decrease of steroid dosage.
Effect on Arthritis
There were no significant differences between the effects of treatment with nialamide and placebo in the parameters measured over the trial period. Strength of grip showed a marked placebo effect in the first 4 weeks, and during the period of steroid reduction a significant fall, but there was no evidence to suggest that nialamide did anything to compensate for the decrease in strength of grip which followed reduction in dosage.
Psychiatric Assessment
One of the outstanding features of this investigation was the number of patients who exhibited depressive aspects of their illness on careful psychiatric evaluation. Out of the thirty patients only two experienced no depressive symptoms.
In both groups a number of patients experienced definite improvement in depressive symptoms during the total period of observation (eight receiving nialamide, five receiving placebo).
Over the whole 8-week period no significant Relationship between Psychiatric and Arthritic Change It is of great interest that there was a significant correlation between changes in psychiatric assessment and subjective arthritic status, these respective changes being ascertained independently by the psychiatrist and physician. There was no such correlation with assessments which were objective.
Strength of grip, which might have been expected to show a correlation with the psychiatric assessment in view of the known importance of psychological factors in limiting the expression of human strength (Ikai and Steinhaus, 1961) , showed a significant correlation only in the nialamide group and only in the first 4 weeks.
Toxicity
Attention was paid to the possibility of liver damage in view of the reports concerning iproniazid and other monoamine oxidase inhibitors by Popper (1958) and Holdsworth, Atkinson, and Goldie (1961) , who indicated that this complication could be fatal. The only side-effect with nialamide which was sufficiently serious to necessitate withdrawal from this trial was postural dizziness in one patient.
Conclusions
Before recommending the addition of another potentially dangerous drug to the list of those already employed in the treatment of rheumatoid arthritis, it is essential that there be evidence of real benefit to the patient. It would appear from the present study that any "steroid sparing" action on the part of nialamide does not act by means of a direct biochemical mechanism in which it interacts with corticosteroids, but rather by an elevation of mood and increased tolerance of pain.
We have been impressed by the high incidence of depression in subjects with chronic rheumatoid arthritis. This is not infrequently overlooked and we believe that more attention needs to be paid to this factor in these patients. It is for a well-defined indication such as this that antidepressive drugs should be used.
Summary
The efficacy of nialamide as a "steroid sparing" agent in the treatment of rheumatoid arthritis has been studied in thirty patients by a double-blind controlled trial.
The patients received 50 mg. nialamide three times daily, or a placebo, in addition to their normal dose of corticosteroid for 4 weeks; the dose of corticosteroid was then reduced by one-third and nialamide or the placebo continued in the same dose. Arthritic and psychiatric assessments were made at the beginning of the trial and at the end of each 4-week period.
There was no evidence that nialamide acted as a steroid sparing agent. A striking correlation was found, however, between psychiatric and subjective arthritic changes, and it is suggested that any apparent steroid sparing action reported by others may be due to elevation of mood rather than to a direct biochemical interaction. Nialamida como agente de "ahorro de esteroides" en el tratamineto de la artritis reumatoide SUMARIO La eficacia de la nialamida como agente de "ahorro de esteroides" en el tratamiento de la artritis reumatoide fue estudiada en treinta enfermos en un ensayo terapeutico por el metodo de double blind.
Los enfermos recibieron 50 mg. de nialamida tres veces al dia o un producto inerte de control, por encima de su dosis normal de corticosteroides, durante cuatro semanas; luego la dosis de corticosteroide fue disminuida de una tercera sin cambiar la de la nialamida o del producto inerte. Se efectuaron valoraciones de la artritis y del estado mental al principio del ensayo y al cabo de cada periodo de 4 semanas.
No se encontraron datos indicando que la nialamida obre como agente de ahorro de esteroides. Se observ6 sin embargo una correlaci6n asombrosa entre las alteraciones psiquiatricas y las artriticas sujetivas y se piensa que toda acci6n aparente de ahorro de esteroides, relatada por otros autores, se debe a un efecto de euforia mas bien que a una acci6n bioquimica directa.
